RD Motif Peptide Conjugated Optical Imaging Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for imaging and targeting integrin expression, particularly in cancer and angiogenesis, face challenges due to the limitations of nuclear imaging with radiopharmaceuticals, including regulatory and handling issues, and the impact of large NIR molecular probes on biodistribution and activity.
Innovation Solution
Development of compounds with peptides containing RD or RGD motifs conjugated to imaging or treatment agents, such as cypate, which selectively target cells expressing integrins, allowing for optical imaging and potential treatment of integrin-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radiopharmaceuticals are used for imaging, then imaging sensitivity is improved, but regulatory and handling complexity increases
Solution Approach 1:
The patent replaces radiopharmaceutical-based nuclear imaging with optical imaging agents that utilize fluorescence or light emission. This substitution eliminates the need for radioactive material handling, regulatory compliance for radiopharmaceuticals, and specialized infrastructure, while maintaining the ability to detect and image integrin expression through optical detection methods
Solution Approach 2:
The patent introduces optical imaging agents as intermediaries between the integrin target and the detection system. These agents comprise fluorophores or light-emitting molecules conjugated to integrin-targeting moieties, serving as safe and accessible mediators that translate molecular binding events into detectable optical signals without requiring radioactive isotopes
2Temperature
If large NIR molecular probes are used, then deep tissue imaging capability is improved, but biodistribution and bioactivity are compromised
Solution Approach 1:
The patent segments the imaging agent into distinct functional components: a small, bioactive peptide or small molecule targeting moiety (such as RGD peptide sequences) conjugated to a fluorophore. This segmentation allows the peptide portion to maintain high affinity binding to integrins while the fluorophore provides optical detection, achieving both deep tissue penetration and reliable target-specific accumulation
Solution Approach 2:
The patent optimizes the molecular size and physical parameters of the imaging agent to balance deep tissue penetration with preserved bioactivity. By using fluorophores with appropriate molecular weights and conjugating them to small peptide carriers rather than large macromolecular probes, the agent achieves sufficient tissue penetration while maintaining high affinity binding and favorable biodistribution characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds enable specific targeting and monitoring of integrin-expressing cells and tissues, offering a viable alternative to nuclear imaging with improved safety and accessibility, while minimizing nonspecific distribution and maintaining bioactivity.
Implementation Method 1
Numerous studies have shown that ABI and more than 7 other heterodimeric integrins recognize proteins and low molecular weight ligands containing RGD (arginine-glycine-aspartic acid) motifs in proteins and small peptides
Implementation Method 2
Optical imaging for biomedical applications typically relies on activating chromophore systems with low energy radiation between 400 and 1500 nm wavelengths and monitoring the propagation of light in deep tissues
Implementation Method 3
the peptide conjugated to an agent selected from an imaging agent and a targeting agent
Data Source
AI summary
The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compounds may be used to detect, monitor and treat a variety of disorders mediated by integrins.